CA-125


Also found in: Wikipedia.

CA-125

Abbreviation for cancer antigen 125 and the test for it. See: cancer antigen 125 test.

MUC16

A gene on chromosome 19p13.2 which encodes a protein that provides a protective lubricating barrier against particles and infectious agents at mucosal surfaces. It is more commonly known as CA125, and is a highly characteristic marker of ovarian carcinomas.

CA-125

A cell surface glycoprotein expressed on the cell membrane of normal ovarian tissue, ovarian, cervical, endometrium, GI tract, and breast CAs; rising levels indicate a poor prognosis, but low levels are of little clinical utility; CA-125 may also be ↑ in liver disease, acute pancreatitis, renal failure, occasionally in normal ♀, lymphoma
References in periodicals archive ?
9, CA-125, CEA, Cortisol, C-peptide, S-DHEA, Ferritin, Folate, FT3, FT4, TSH , HCG, IgE, Insulin, LH, FSH, E2, PTH, progesterone, PRL, PSA free PSA CAL key.
The risk of ovarian cancer algorithm (ROCA) compares an individual's CA-125 serial profile with that of cancer cases and healthy controls to estimate a risk for ovarian cancer.
The test is twice as effective in identifying cancers than the traditional method of simply measuring CA-125 levels where clinicians consider values above 35 unit per ml to be worrisome.
The serum CA-125 level is not specific and does not always increase (6).
Women with a close family member who has battled one of these cancers are at a higher risk, and we urge them to request the CA-125 and HE4 blood test, as well as a transvaginal ultrasound.
Ovarian cancer growth-related and cancer antigen 125 (CA-125)-related parameters from the published literature were used to "prime the model," thereby establishing the "baseline parameters" for the earliest detection time or the smallest tumor diameter or volume that could be detected by current CA-125 ELISA assays.
women was not significantly reduced by annual screening with transvaginal ultrasound and serum CA-125 testing.
I was disappointed that CA-125 as a monitor was not included.
New results from the National Cancer Institute-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial show that screening for ovarian cancer with transvaginal ultrasound (TVU) and the CA-125 blood test did not result in fewer deaths from the disease compared with usual care.
Twenty-three percent of patients on a dose schedule of once every three weeks saw substantial shrinkage in their tumors, and 38% saw a marked reduction in the ovarian cancer biomarker CA-125.
Anderson Cancer Center discovered a new way to use the cancer antigen or CA-125 test, which measures levels of a protein that is elevated in ovarian cancer cells.